WASHINGTON (December 16, 2024) – AIDS Healthcare Foundation (AHF) welcomes the U.S. Health Resources and Services Administration move against Sanofi’s attack on the 340B Drug Pricing Program. In a letter to Sanofi HRSA Letter to Paul Hudson HRSA warned Sanofi that if it proceeds with converting 340B from a discount to a rebate program, it will no longer have access to the lucrative and highly profitably taxpayer-supported Medicare and Medicaid prescription drug markets. HRSA wrote “ … this unapproved credit proposal violates Sanofi’s obligations under the 340B statute….”
“Sanofi joins Bristol Myers Squibb, Johnson & Johnson and Eli Lilly and Company in their latest attempt to strangle the 340B Drug Pricing Program that is the backbone of the country’s healthcare safety net. The blatant actions of these four highly profitable drug industry giants reveals what we all know, that drug companies will never stop trying to kill 340B,” said John Hassell, AHF’s national director of advocacy. “AHF is grateful that HRSA is drawing a bright line in the sand on the industry’s latest attack on 340B.”
